• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab plus chemotherapy for advanced gastric cancer.

作者信息

Huang Chen-Yu, Wu Xiao-Bing

机构信息

Department of Gastrointestinal Surgery, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, and The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510150, China.

Department of Gastrointestinal Surgery, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, and The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510150, China.

出版信息

Lancet Oncol. 2024 Feb;25(2):e50. doi: 10.1016/S1470-2045(23)00573-9.

DOI:10.1016/S1470-2045(23)00573-9
PMID:38301692
Abstract
摘要

相似文献

1
Pembrolizumab plus chemotherapy for advanced gastric cancer.帕博利珠单抗联合化疗治疗晚期胃癌。
Lancet Oncol. 2024 Feb;25(2):e50. doi: 10.1016/S1470-2045(23)00573-9.
2
Pembrolizumab plus chemotherapy for advanced gastric cancer.帕博利珠单抗联合化疗治疗晚期胃癌。
Lancet Oncol. 2024 Feb;25(2):e51. doi: 10.1016/S1470-2045(23)00621-6.
3
Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.帕博利珠单抗联合化疗治疗晚期胃癌——作者回复
Lancet Oncol. 2024 Feb;25(2):e52. doi: 10.1016/S1470-2045(24)00022-6.
4
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.雷莫芦单抗联合帕博利珠单抗治疗既往治疗的晚期非小细胞肺癌、胃食管交界处癌或尿路上皮癌患者（JVDF）：一项多队列、非随机、开放标签、1a/1b 期临床试验。
Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
5
Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.帕博利珠单抗治疗晚期肺癌患者的真实世界经验
Am J Ther. 2019 Jul/Aug;26(4):e537-e538. doi: 10.1097/MJT.0000000000000762.
6
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.帕博利珠单抗联合多西他赛对比多西他赛单药用于既往治疗的晚期非小细胞肺癌患者的疗效和安全性：PROLUNG 期 2 随机临床试验。
JAMA Oncol. 2020 Jun 1;6(6):856-864. doi: 10.1001/jamaoncol.2020.0409.
7
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.在程序性死亡受体配体1（PD-L1）表达≥50%的非小细胞肺癌患者中，一线使用帕博利珠单抗联合或不联合铂类双药化疗。
Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.
8
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.对于 PD-L1 高表达的晚期非小细胞肺癌患者的一线治疗：帕博利珠单抗或帕博利珠单抗联合化疗。
J Immunother Cancer. 2019 May 3;7(1):120. doi: 10.1186/s40425-019-0600-6.
9
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
10
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.KEYNOTE-021 队列 G：培美曲塞和卡铂联合或不联合帕博利珠单抗作为一线治疗晚期非鳞状非小细胞肺癌的 24 个月总生存数据。
J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.

引用本文的文献

1
The cGAS/STING Pathway-A New Potential Biotherapeutic Target for Gastric Cancer?cGAS/STING通路——胃癌的一个新的潜在生物治疗靶点？
J Pers Med. 2024 Jul 9;14(7):736. doi: 10.3390/jpm14070736.